Question 1
A 34-year-old woman with moderate persistent asthma presents for regular follow-up. She experiences daytime wheezing and dyspnea 3 to 4 days per week and wakes up coughing once a week. She currently uses low-dose inhaled budesonide (200 mcg twice daily) and as-needed salbutamol. According to the Global Initiative for Asthma (GINA) Track 1 recommendations, what is the most appropriate management step?
Correct Answer:
Switch to low-dose budesonide-formoterol as both daily maintenance and as-needed reliever (MART strategy)
Question 2
A 48-year-old non-smoker with severe refractory asthma has experienced three oral corticosteroid-treated exacerbations in the past 12 months despite adherence to high-dose fluticasone-salmeterol plus tiotropium. Peripheral blood testing reveals an absolute eosinophil count of 480 cells/µL (0.48 × 10⁹/L), total serum IgE of 42 IU/mL, and fractional exhaled nitric oxide (FeNO) of 38 ppb. Skin prick testing for common aeroallergens is negative. Which biologic therapy is most specifically indicated for this patient's phenotype?
Correct Answer:
Mepolizumab or Benralizumab (targeting the IL-5 pathway)
Question 3
A 26-year-old male with perennial allergic rhinitis and severe allergic asthma requires frequent short courses of systemic corticosteroids. Laboratory evaluation shows total serum IgE of 320 IU/mL, blood eosinophils 210 cells/µL, and positive RAST testing for Dermatophagoides pteronyssinus. Before initiating omalizumab, how is the correct therapeutic dose and administration frequency determined?
Correct Answer:
Body weight and baseline pre-treatment total serum IgE level using a standardized dosing nomogram
Question 4
A 52-year-old woman with severe asthma, recurrent chronic rhinosinusitis with nasal polyps (CRSwNP), and maintenance oral corticosteroid dependence (prednisone 10 mg daily) is evaluated for biologic therapy. Her FeNO is 65 ppb and blood eosinophils are 350 cells/µL. Which biologic targeting the alpha subunit of the interleukin-4 receptor (IL-4Rα) inhibits both IL-4 and IL-13 signaling and is highly effective at reducing oral steroid dependence and nasal polyp burden?
Correct Answer:
Dupilumab
Question 5
A 45-year-old man has severe uncontrolled asthma with frequent winter exacerbations. Biomarker testing repeatedly demonstrates blood eosinophils
Correct Answer:
Tezepelumab
Question 1
Exam overview

About this Exam

Prepare with the Facharzt FMH Pneumologie Practice Questions - Facharzt FMH für Pneumologie Spécialiste FMH en pneumologie Exam practice quiz. This question bank includes 100 questions covering year-old, pulmonary, presents, dyspnea, and reveals. Use it to review important concepts, identify knowledge gaps, and build confidence for the related exam, course, or assessment.

More details

Additional Information

Facharzt FMH Pneumologie Practice Questions - Facharzt FMH für Pneumologie Spécialiste FMH en pneumologie Exam

This practice set contains 100 questions from the matching question bank and focuses on year-old, pulmonary, presents, dyspnea, and reveals. Work through each question carefully, review the provided solutions, and revisit topics that need more study before your next attempt.

This is an independent study resource intended for practice and review; it is not an official examination or an endorsement by any organization named in the title.

Quiz information

Frequently Asked Questions

The complete question count is available after full access is unlocked.
No fixed duration is currently configured for this quiz.
Question explanations are included where they are available in the quiz content, helping you review the reasoning after answering.
Yes. You can retake the practice test again as you continue studying during your available access period.
After your access is confirmed, you can continue into the complete practice exam from this quiz flow.
Unless explicitly stated otherwise, this page provides independent practice material for study and exam preparation and is not the official examination itself.
Keep studying

Related Questions